A Randomised, Double-blind, Double-dummy, Three-period Cross-over Trial to Compare Post Prandial Blood Glucose Control of BioChaperone Combo With Humalog Mix25 and With Simultaneous Injections of Humalog and Lantus in Subjects With Type 2 Diabetes

Trial Profile

A Randomised, Double-blind, Double-dummy, Three-period Cross-over Trial to Compare Post Prandial Blood Glucose Control of BioChaperone Combo With Humalog Mix25 and With Simultaneous Injections of Humalog and Lantus in Subjects With Type 2 Diabetes

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Jul 2017

At a glance

  • Drugs Insulin glargine/insulin lispro (Primary) ; Insulin glargine; Insulin lispro; Insulin neutral protamine lispro/insulin lispro
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Sponsors Adocia
  • Most Recent Events

    • 28 Jun 2017 Status changed from recruiting to completed.
    • 06 Jun 2017 Primary endpoint (Delta AUC BG 0-2h (area under the blood glucose concentration-time curve)) has been met according to an Adocia media release.
    • 06 Jun 2017 Results published in an Adocia media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top